Literature DB >> 18635965

Moderate variations in CDC25B protein levels modulate the response to DNA damaging agents.

Bernadette Aressy1, Béatrix Bugler, Annie Valette, Denis Biard, Bernard Ducommun.   

Abstract

CDC25B, one of the three members of the CDC25 dual-specificity phosphatase family, plays a critical role in the control of the cell cycle and in the checkpoint response to DNA damage. CDC25B is responsible for the initial dephosphorylation and activation of the cyclin-dependent kinases, thus initiating the train of events leading to entry into mitosis. The critical role played by CDC25B is illustrated by the fact that it is specifically required for checkpoint recovery and that unscheduled accumulation of CDC25B is responsible for illegitimate entry into mitosis. Here, we report that in p53(-/-) colon carcinoma cells, a moderate increase in the CDC25B level is sufficient to impair the DNA damage checkpoint, to increase spontaneous mutagenesis, and to sensitize cells to ionising radiation and genotoxic agents. Using a tumour cell spheroid assay as an alternative to animal studies, we demonstrate that the level of CDC25B expression modulates growth inhibition and apoptotic death. Since CDC25B overexpression has been observed in a significant number of human cancers, including colon carcinoma, and is often associated with high grade tumours and poor prognosis, our work suggests that the expression level of CDC25B might be a potential key parameter of the cellular response to cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18635965     DOI: 10.4161/cc.7.14.6305

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  10 in total

Review 1.  Impaired DNA damage response--an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy.

Authors:  Zbigniew Darzynkiewicz; Frank Traganos; Donald Wlodkowic
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

2.  Unscheduled expression of CDC25B in S-phase leads to replicative stress and DNA damage.

Authors:  Béatrix Bugler; Estelle Schmitt; Bernadette Aressy; Bernard Ducommun
Journal:  Mol Cancer       Date:  2010-02-04       Impact factor: 27.401

3.  RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B.

Authors:  C F Wu; S Liu; Y-C Lee; R Wang; S Sun; F Yin; W G Bornmann; L-Y Yu-Lee; G E Gallick; W Zhang; S-H Lin; J Kuang
Journal:  Oncogene       Date:  2013-05-27       Impact factor: 9.867

4.  Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.

Authors:  Paul A Johnston; Caleb A Foster; Marni Brisson Tierno; Tong Ying Shun; Sunita N Shinde; William D Paquette; Kay M Brummond; Peter Wipf; John S Lazo
Journal:  Assay Drug Dev Technol       Date:  2009-06       Impact factor: 1.738

5.  Elevated cyclin G2 expression intersects with DNA damage checkpoint signaling and is required for a potent G2/M checkpoint arrest response to doxorubicin.

Authors:  Maike Zimmermann; Aruni S Arachchige-Don; Michaela S Donaldson; Robert F Dallapiazza; Colleen E Cowan; Mary C Horne
Journal:  J Biol Chem       Date:  2012-05-15       Impact factor: 5.157

6.  Overexpression of mutant cell division cycle 25 homolog B (CDC25B) enhances the efficiency of selection in Chinese hamster ovary cells.

Authors:  Kyoung Ho Lee; Tomomi Tsutsui; Kohsuke Honda; Hisao Ohtake; Takeshi Omasa
Journal:  Cytotechnology       Date:  2013-11-19       Impact factor: 2.058

7.  Ligand-based chemoinformatic discovery of a novel small molecule inhibitor targeting CDC25 dual specificity phosphatases and displaying in vitro efficacy against melanoma cells.

Authors:  Alessandra Capasso; Carmen Cerchia; Carmen Di Giovanni; Giuseppina Granato; Francesco Albano; Simona Romano; Emmanuele De Vendittis; Maria Rosaria Ruocco; Antonio Lavecchia
Journal:  Oncotarget       Date:  2015-11-24

8.  CDC25B partners with PP2A to induce AMPK activation and tumor suppression in triple negative breast cancer.

Authors:  Junmei Cairns; Reynold C Ly; Nifang Niu; Krishna R Kalari; Erin E Carlson; Liewei Wang
Journal:  NAR Cancer       Date:  2020-12-21

9.  Grouped graphical Granger modeling for gene expression regulatory networks discovery.

Authors:  Aurélie C Lozano; Naoki Abe; Yan Liu; Saharon Rosset
Journal:  Bioinformatics       Date:  2009-06-15       Impact factor: 6.937

10.  Integrated analysis of copy number variation and genome-wide expression profiling in colorectal cancer tissues.

Authors:  Nur Zarina Ali Hassan; Norfilza Mohd Mokhtar; Teow Kok Sin; Isa Mohamed Rose; Ismail Sagap; Roslan Harun; Rahman Jamal
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.